Ondine Biomedical Inc
LSE:OBI
Intrinsic Value
The intrinsic value of one OBI stock under the Base Case scenario is 4.83 GBX. Compared to the current market price of 10.25 GBX, Ondine Biomedical Inc is Overvalued by 53%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Ondine Biomedical Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Ondine Biomedical Inc
Balance Sheet Decomposition
Ondine Biomedical Inc
Current Assets | 3.2m |
Cash & Short-Term Investments | 1.2m |
Receivables | 238k |
Other Current Assets | 1.8m |
Non-Current Assets | 803k |
PP&E | 767k |
Other Non-Current Assets | 36k |
Free Cash Flow Analysis
Ondine Biomedical Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
Ondine Biomedical Inc
Revenue
|
1.6m
CAD
|
Cost of Revenue
|
-653k
CAD
|
Gross Profit
|
981k
CAD
|
Operating Expenses
|
-15.6m
CAD
|
Operating Income
|
-14.6m
CAD
|
Other Expenses
|
331k
CAD
|
Net Income
|
-14.3m
CAD
|
OBI Profitability Score
Profitability Due Diligence
Ondine Biomedical Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Ondine Biomedical Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
OBI Solvency Score
Solvency Due Diligence
Ondine Biomedical Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Ondine Biomedical Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OBI Price Targets Summary
Ondine Biomedical Inc
According to Wall Street analysts, the average 1-year price target for OBI is 56.1 GBX with a low forecast of 55.55 GBX and a high forecast of 57.75 GBX.
Dividends
Current shareholder yield for OBI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one OBI stock under the Base Case scenario is 4.83 GBX.
Compared to the current market price of 10.25 GBX, Ondine Biomedical Inc is Overvalued by 53%.